This site is intended for healthcare professionals

Phase III DERBY and OAKS studies of Empaveli show mixed results in geographic atrophy.- Apellis Pharma

Read time: 1 mins
Last updated:11th Sep 2021
Published:11th Sep 2021
Apellis Pharmaceuticals reported top-line results from the Phase III DERBY and OAKS studies evaluating intravitreal Empaveli (pegcetacoplan), an investigational targeted C3 therapy, in 1,258 adults with geographic atrophy (GA) secondary to age-related macular degeneration (AMD). Monthly and every-other-month treatment with pegcetacoplan met the primary endpoint in OAKS, significantly reducing GA lesion growth by 22% (p=0.0003) and 16% (p=0.0052), respectively, compared to pooled sham at 12 months. DERBY did not meet the primary endpoint, showing a reduction in GA lesion growth of 12% (p=0.0528) and 11% (p=0.0750) with monthly and every-other-month treatment, respectively, compared to pooled sham at 12 months.
Condition: Geographic Atrophy/AMD
Type: drug
Register for free access to this exclusive healthcare learning resource

Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest